# Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

> **NCT06408168** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative
- Metastatic Invasive LObular Carcinoma

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Repotrectinib

## Key facts

- **NCT ID:** NCT06408168
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-08
- **Primary completion:** 2025-12-08
- **Final completion:** 2025-12-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** \<75% Participation
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408168, "Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06408168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*